NDAORALTABLET
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
18
Data completeness
6/8 — Strong
UBRELVY (ubrogepant) by AbbVie is calcitonin gene-related peptide receptor antagonists [moa]. Approved for migraine. First approved in 2019.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UBRELVY (ubrogepant) is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA on December 23, 2019, for the acute treatment of migraine in adults. It represents a novel mechanism of action that interrupts CGRP signaling, a key pathway in migraine pathophysiology. The product is positioned as an acute treatment option for patients seeking an alternative to traditional triptans and other migraine abortive therapies.
$0.3BPart D
15.6 years to LOEMechanism of Action
Calcitonin Gene-related Peptide Receptor Antagonists
Pharmacologic Class:
Calcitonin Gene-related Peptide Receptor Antagonist
Indications (1)
Clinical Trials (18)
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
Started Jan 2026
189 enrolled
Migraine
Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
Started Feb 2025
178 enrolled
Migraine
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
Started Sep 2024
43 enrolled
Migraine
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Started Sep 2024
496 enrolled
Migraine
Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
Started Jul 2023
24 enrolled
Healthy Volunteers
Worked on UBRELVY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.